BioNTech strikes gold again: German biotech company behind the Pfizer Covid-19 jab develops a potential vaccine for multiple sclerosis
-Joe Pinkstone
-Joe Pinkstone
- New jab uses mRNA to stop MS patients' immune systems attacking neurons
- Studies in mice show it stopped disease progression and also reversed some loss of motor function
The experts behind the BioNTech coronavirus jab have developed another vaccine which they claim cures multiple sclerosis (MS) in mice.
The new MS vaccine works in a similar way to the coronavirus vaccine, manufactured in conjunction with US pharmaceutical giant Pfizer.
In the case of the coronavirus vaccine, this protein mimics the virus's protruding spike, kickstarting the immune system to start making antibodies.
If a person later contracts the coronavirus, the immune system rapidly creates antibodies again and fights the infection before it can take hold or spread.
In the case of the coronavirus vaccine, this protein mimics the virus's protruding spike, kickstarting the immune system to start making antibodies.
If a person later contracts the coronavirus, the immune system rapidly creates antibodies again and fights the infection before it can take hold or spread.
In the case of the MS vaccine, the mRNA technology stops the body's own immune system from attacking neurons in the brain and spinal cord which prevents the eventual loss of bodily function.
Clinical trials on mice revealed the jab cured the condition, stopped disease progression and restored some motor skills which had already been lost.
